GPRC5D

GPRC5D

GPRC5D Overview

Molecule Name
G-protein coupled receptor family C group 5member D
Synonyms
GPRC5D,G-protein coupled receptor family C group 5 member D
Drug Development Progress
Drugs in Clinical Trials40
Approved Drugs1
Highest Development StageApproved
Target Synonym
G Protein-Coupled Receptor Class C Group 5 Member D,G-Protein Coupled Receptor Family C Group 5 Member D,G Protein-Coupled Receptor, Class C, Group 5, Member D,G Protein-Coupled Receptor, Family C, Group 5, Member D,GPRC5D,Orphan G-Protein Coupled Receptor
Background
G-protein coupled receptor family C group 5 member D (GPRC5D) is a retinoic acid-inducible 40 kDa protein with seven transmembrane segments and a short N terminal extracellular region. Widely expressed in the peripheral system. Expression pattern is high in pancreas, medium in kidney, small intestine, spleen and testis, low in lung, colon, leukocyte, prostate and thymus and not detectable in brain, heart, liver, placenta, skeletal muscle and ovary.

GPRC5D Product List

Species
  • Human(8)
  • Cynomolgus(2)
  • Mouse(2)
Tag
  • His Tag & Flag Tag(6)
  • -(3)
  • His Tag & Avi Tag & Flag Tag(2)
  • GFP Tag(1)
Host
  • HEK293(12)
Conjugate
  • Unconjugated(7)
  • Biotin-labeled(3)
  • GFP Fusion(1)
  • PE Labeled(1)
Grade
  • RUO(12)
Low Endotoxin
  • No(12)
You Have Viewed 1-10 Of 12 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Antibody Project Trading Platform

Project NameProject StageMolecule TypeMolecule SourceDisease AreaIndication
GPRC5D VHH - 01PCCMonoclonalNanobodyHematological MalignancyMultiple myeloma
Project Name
GPRC5D VHH - 01
Project Stage
PCC
Molecule Type
Monoclonal
Molecule Source
Nanobody
Disease Area
Hematological Malignancy
Indication
Multiple myeloma
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital)Phase 3 ClinicalPeking University People'S Hospital
Acquired thrombotic thrombocytopenic purpura; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Behcet Syndrome; Carcinoma, Transitional Cell; Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic; Myositis; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome
Details
QLS-32015QLS-32015; QLS32015Phase 3 ClinicalQilu Pharmaceutical Co Ltd
Multiple Myeloma
Details
RamantamigJNJ-79635322; JNJ-5322Phase 3 ClinicalJanssen Research & Development Llc
Multiple Myeloma
Details
Arlocabtagene autoleucelBMS986393; BMS-986393; CC-95266Phase 3 ClinicalJuno Therapeutics Inc
Multiple Myeloma
Details
LM-305LM-305Phase 2 ClinicalLaNova Medicines Ltd
Multiple Myeloma
Details
REGN-17372REGN17372; REGN-17372Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Multiple Myeloma
Details
GPRC5D/CD3 BiTEsGPRC5D/CD3 BiTEsPhase 2 ClinicalInstitute Of Hematology & Blood Diseases Hospital
Multiple Myeloma
Details
BCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech)Phase 2 ClinicalEssen Biotech
Multiple Myeloma
Details
BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General Hospital
Multiple Myeloma
Details
CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute)Phase 2 ClinicalShenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health
Multiple Myeloma; Plasmacytoma
Details
AZD-0305AZD0305; AZD-0305Phase 2 ClinicalAstrazeneca Plc
Multiple Myeloma
Details
Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co Ltd
Multiple Myeloma
Details
IBI-3003IBI3003; IBI-3003Phase 2 Clinical
Multiple Myeloma
Details
BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene)Phase 2 ClinicalGuangzhou Bio-Gene Technology Co Ltd
Multiple Myeloma
Details
MBS-314MBS-314Phase 2 ClinicalBeijing Mabworks Biotech Co Ltd
Multiple Myeloma
Details
CT-071CT071; CT-071Phase 2 ClinicalCARsgen Therapeutics Holdings Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
Anti-GPRC5D CAR-T Cells Therapy(Institute of Hematology & Blood Diseases Hospital)Phase 2 ClinicalInstitute Of Hematology & Blood Diseases Hospital
Multiple Myeloma
Details
Anti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co Ltd
Multiple Myeloma
Details
Ori-CAR-017Ori-CAR-017; GPRC5D-CAR-TPhase 2 ClinicalOriCell Therapeutics Co Ltd
Blood Protein Disorders; Cardiovascular Diseases; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Immune System Diseases; Immunoproliferative Disorders; Lymphoproliferative Disorders; Multiple Myeloma; Neoplasms; Paraproteinemias; Vascular Diseases
Details
LBL-034LBL-034Phase 2 ClinicalNanjing Leadsbiolabs Co Ltd
Multiple Myeloma; Neoplasms
Details
anti-GPRC5D CAR T-cell Therapy (Dana-Farber Cancer Institute/Memorial Sloan Kettering Cancer Center/Roswell Park Comprehensive Cancer Center)Phase 1 ClinicalDana-Farber Cancer Institute
Multiple Myeloma
Details
anti-GPRC5D CAR T-cell therapy (Bristol Myers Squibb)Phase 1 ClinicalBristol-Myers Squibb Company
Multiple Myeloma
Details
O&D-001O&D-001Phase 1 ClinicalO&D BioTech Group Co Ltd
Multiple Myeloma
Details
SL-0439SL0439; SL-0439Phase 1 ClinicalHebei Senlang Biological Technology Co Ltd
Multiple Myeloma
Details
TQB-2029TQB2029; TQB-2029Phase 1 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Multiple Myeloma
Details
SAR-446523SAR-446523Phase 1 ClinicalSanofi-Aventis Gmbh
Bone Marrow Neoplasms; Multiple Myeloma
Details
CM-380CM380; CM-380Phase 1 ClinicalKeymed Biosciences Co Ltd
Multiple Myeloma
Details
OL-101OL-101Phase 1 ClinicalOverland Pharmaceuticals (Shanghai) Co Ltd
Multiple Myeloma
Details
QLS-4131QLS-4131; QLS4131Phase 1 ClinicalQilu Pharmaceutical Co Ltd
Lupus Erythematosus, Systemic; Multiple Myeloma
Details
RD-140RD140Phase 1 ClinicalNanjing Iaso Biotherapeutics Co Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province)Phase 1 ClinicalThe Second People Hospital Of Guangdong Province
Multiple Myeloma
Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics)BMS-986453Phase 1 ClinicalJuno Therapeutics Inc
Multiple Myeloma
Details
SIM-0500SIM-0500; SIM0500Phase 1 ClinicalSimcere Pharmaceutical Group Ltd
Bone Marrow Neoplasms; Multiple Myeloma
Details
Anti-GPRC5D CAR-T Cells Therapy (Guangzhou Bio-Gene Technology Co Ltd)Phase 1 ClinicalGuangzhou Bio-Gene Technology Co Ltd
Multiple Myeloma
Details
OriC-321OriC-321; Ori-C-321Phase 1 ClinicalOriCell Therapeutics Co Ltd, Zhejiang University
Multiple Myeloma
Details
CAR-GPRC5DCAR-GPRC5D; RD-118; RD118Phase 1 ClinicalNanjing Iaso Biotherapeutics Co Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
ForimtamigRG-6234Phase 1 ClinicalF. Hoffmann-La Roche Ltd
Multiple Myeloma
Details
MCARH-109Phase 1 ClinicalEureka Therapeutics Inc, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Details
RO-7425781RO-7425781Phase 1 ClinicalF. Hoffmann-La Roche Ltd
Multiple Myeloma
Details
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics)ACT-001(Acellytron Therapeutics)ClinicalAcellytron Therapeutics
Multiple Myeloma
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
TalquetamabJNJ-7564; JNJ-64407564ApprovedGenmab A/S, Johnson & Johnson Innovative MedicineTALVEY, 拓立珂United StatesMultiple MyelomaJanssen Biotech Inc2023-08-09
Hematologic Neoplasms; Multiple Myeloma
Details
Customer Reviews
  • E***n2025-07-31
    Great product and fantastic service. Product worked well following delivery and solved some of the issues we've been experiencing with assays. Service was also highly commendable, with us receiving our order just days after placing it. Technical recommendations were also very useful in deciding which variant of the protein would be best suited for our assays.